MBGroup3, MBGroup4 and MBSHH patients with high expression levels of YB-1 mRNA had significantly worse 10-year overall survival outcomes than those with low YB-1 expression levels (Figure 1B–D), indicative of YB-1 oncogenic potential in medulloblastoma. The gene discussed is YBX1; the disease is medulloblastoma.